Pharma Promotion / Incidents by company / Boehringer Ingelheim
Boehringer Ingelheim
3 incidents / jurisdictions: European Union, United States / sum of amounts reported: USD 745.0 m
| Date | Jurisdiction | Outcome | What happened (source) | Damages / settlement / fine |
|---|---|---|---|---|
| 2023 | European Union | Fine / administrative sanction | In October 2023 Boehringer Ingelheim was ordered to pay a 10 million Euro fine for illegal price fixing that had gone on globally over a period of nearly fifteen years. Boehringer bears the largest sh Wikipedia: Boehringer Ingelheim（Litigation） | — |
| 2012 | United States | Settlement | In October 2012 Boehringer Ingelheim settled a "qui tam" (whistleblower) case with the U.S. government for $95 million alleging "off-label" marketing of the drugs Aggrenox, Atrovent, Combivent, and Mi Wikipedia: Boehringer Ingelheim（Litigation） + 1 more reports | $95 million |
| 2012 | United States | Settlement | In August 2012, Pradaxa claims filed in the federal court were consolidated in a multi-district litigation in the Southern District of Illinois before Chief Judge David R. Herndon. On 28 May 2014, a $ Wikipedia: Boehringer Ingelheim（Litigation） | $650 million |
Amounts are extracted mechanically from headlines and summaries and kept only when Jev confirms they are paid by the company. The same case reported by several articles may be counted more than once, so totals are indicative. Check the sources.